Stocks and Investing
Stocks and Investing
Tue, April 9, 2013
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 06:00 AM ] - Market Wire
[ 05:45 AM ] - WOPRAI
[ 05:45 AM ] - WOPRAI
[ 05:30 AM ] - Market Wire
[ 05:00 AM ] - Market Wire
[ 04:33 AM ] - Market Wire
[ 03:47 AM ] - WOPRAI
[ 03:46 AM ] - WOPRAI
[ 03:46 AM ] - WOPRAI
[ 03:46 AM ] - WOPRAI
[ 03:45 AM ] - WOPRAI
[ 03:45 AM ] - WOPRAI
[ 12:23 AM ] - Market Wire
[ 12:03 AM ] - Market Wire
[ 12:00 AM ] - WOPRAI
Brian Abrahams Maintained (BIIB) at Buy with Increased Target to $215 on, Apr 9th, 2013
Brian Abrahams of RBC Capital, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $180 to $215 on, Apr 9th, 2013.
Brian has made no other calls on BIIB in the last 4 months.
There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
- Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
These are the ratings of the 4 analyists that currently disagree with Brian
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $225 on, Thursday, April 4th, 2013
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $206 on, Monday, April 1st, 2013
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $188 on, Monday, March 25th, 2013
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013